{"nctId":"NCT02435992","briefTitle":"Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis","startDateStruct":{"date":"2015-06-17","type":"ACTUAL"},"conditions":["Ulcerative Colitis"],"count":1012,"armGroups":[{"label":"RPC1063 (Ozanimod)","type":"EXPERIMENTAL","interventionNames":["Drug: RPC1063"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"RPC1063","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 18 to 75 years (at screening for Cohort 1 and 2)\n* UC confirmed on endoscopy\n* Moderately to severely active UC (May score 6-12)\n* Currently receiving treatment with aminosalisylate, prednisone, or budesonide\n* Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization\n\nExclusion Criteria:\n\n* Have severe extensive colitis as evidence by:\n* Physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline.\n* Current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation.\n* Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis\n* Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk\n* History of uveitis or unknown macular edema\n* Pregnancy, lactation, or a positive serum β-human chorionic gonadotropin (β-hCG) measured during screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in Clinical Remission at 10 Weeks","description":"Percentage of participants that are in Clinical remission at 10 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"6.0","spread":null},{"groupId":"OG002","value":"21.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in Clinical Remission at 52 Weeks","description":"Percentage of participants that are in Clinical remission at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"24.6","spread":null},{"groupId":"OG003","value":"37.0","spread":null},{"groupId":"OG004","value":"18.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Response at 10 Weeks","description":"Percentage of participants that are in Clinical response at 10 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null},{"groupId":"OG001","value":"25.9","spread":null},{"groupId":"OG002","value":"52.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Endoscopic Improvement at 10 Weeks","description":"Percentage of participants with endoscopic improvement at 10 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"27.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing at 10 Weeks","description":"Percentage of participants with mucosal healing at 10 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG002","value":"11.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Clinical Response at 52 Weeks","description":"Percentage of participants that are in Clinical response at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"39.1","spread":null},{"groupId":"OG003","value":"60.0","spread":null},{"groupId":"OG004","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Endoscopic Improvement at 52 Weeks","description":"Percentage of participants with endoscopic improvement at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"29.0","spread":null},{"groupId":"OG003","value":"45.7","spread":null},{"groupId":"OG004","value":"26.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Clinical Remission at Week 52 Who Were in Remission at Week 10","description":"Percentage of participants in clinical remission at week 52 who were in clinical remission at week 10","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"41.7","spread":null},{"groupId":"OG003","value":"51.9","spread":null},{"groupId":"OG004","value":"29.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Corticosteroid Free Remission at 52 Weeks","description":"Percentage of participants with corticosteroid free remission at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"24.6","spread":null},{"groupId":"OG003","value":"31.7","spread":null},{"groupId":"OG004","value":"16.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing at 52 Weeks","description":"Percentage of participants with Mucosal Healing at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG003","value":"29.6","spread":null},{"groupId":"OG004","value":"14.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Durable Clinical Remission at 52 Weeks","description":"Percentage of participants with durable clinical remission at 52 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"7.2","spread":null},{"groupId":"OG003","value":"17.8","spread":null},{"groupId":"OG004","value":"9.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":429},"commonTop":["Anaemia"]}}}